Thetis is a biopharmaceutical company developing novel, small molecule oral therapies for the treatment of inflammatory diseases.
Thetis’ proprietary HEALER technology platform enables the pharmaceutical development of bioactive lipids that actively regulate inflammation and tissue repair, including Specialized Pro-Resolving Mediators (SPMs) and their Omega-3 precursors. Thetis’s technology overcomes the stability, manufacturing, formulation and patentability hurdles that have limited the development of bioactive lipids as pharmaceutical agents, unlocking their robust pharmacology to be developed as first-in-class therapeutics.
Thetis’ lead candidate, TP-317, is a potential first-in-class, Resolvin-based agent targeted at Inflammatory Bowel Disease (IBD), a set of chronic, relapsing gastrointestinal inflammatory disorders that includes ulcerative colitis and Crohn’s Disease. TP-317 offers a new approach to treating IBD based on resolving inflammation and promoting mucosal healing without compromising immune function, a major problem with existing immunosuppressive therapies. TP-317 is positioned as a safe, oral therapy for IBD patients before they escalate to biologics and other immunosuppressive agents. Thetis was recently awarded a $2.3 million Fast Track NIH grant supporting TP-317 development.
In addition, Thetis has two Omega-3 based oral agents in development. TP-352 is a novel derivative of docosahexaenoic acid (DHA), which has been shown in NASH patients to be effective in reducing liver steatosis, aminotransferases, histological inflammation, and other disease markers. This clinical POC data and the expected safety profile of TP-352 together provide the foundation for advancement as a potential first-line therapy in NASH. TP-252 is a novel derivative of eicosapentaenoic acid (EPA), which has been shown to reduce the relapse rate in ulcerative colitis patients and reduce the risk of cardiovascular events in patients with mixed dyslipidemia. TP-252 is funded by a $1.9 million Fast Track NIH grant.